company, announced today that magnetic resonance imaging (MRI) data from
the Phase III TEMSO study demonstrate that Aubagio®
(teriflunomide) significantly slowed brain volume loss (or atrophy) vs.
placebo over two years in people with relapsing...
company, today announced a new global initiative, vs.MS, that is
designed to raise awareness of the often unspoken emotional and physical
burden of relapsing multiple sclerosis (RMS) on people living with the
disease and their care partners. To...
Paris, France and Cambridge, Mass. - October 1st, 2015 - Sanofi and its subsidiary Genzyme announced today that Genzyme has elected to opt into Alnylam's investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western...
company, announced today that new investigational data on its marketed
treatments, Aubagio® (teriflunomide) and Lemtrada®
(alemtuzumab), as well as data from the company’s MS pipeline, will be
presented during the 31st Congress of the European...